Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart

Gregory K. Asimakis, Donald J. DiPette, Vincent Conti, O. Bryan Holland, Joseph B. Zwischenberger

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The effects of calcitonin gene-related peptide (CGRP) on heart rate, coronary flow, pressure development, and time to ischemic contracture were studied in the isolated, perfused rat heart. A bolus of CGRP (2640 pmols) caused significant increases in heart rate and coronary flow; these effects were sustained for at least five minutes after injection. The increase in coronary flow was independent of heart rate, since CGRP caused an increase in coronary flow in non-beating (potassium-arrested) hearts. The dose-response of CGRP was studied using five doses (65, 218, 658, 1320 and 2640 pmols) given as bolus injections. Although the increase in heart rate was apparently dose-dependent, significant increases above baseline were observed only with the two highest doses. In contrast, coronary flow increased significantly above baseline with the injection of all but the lowest dose of CGRP. Ten minutes after injection of CGRP, all hearts were made ischemic. The time to onset of ischemic contracture was approximately 11 minutes for those hearts that received 65 pmols CGRP; however, for those hearts receiving all other doses of CGRP, the time to onset of contracture was approximately 8 minutes. We conclude that CGRP significantly decreases the resistance of the coronary vascular bed, and that it may be an important regulator of regional blood flow in the heart.

Original languageEnglish (US)
Pages (from-to)597-604
Number of pages8
JournalLife Sciences
Volume41
Issue number5
DOIs
StatePublished - Aug 3 1987

Fingerprint

Calcitonin Gene-Related Peptide
Hemodynamics
Rats
Ischemic Contracture
Heart Rate
Injections
Regional Blood Flow
Contracture
Vascular Resistance
Potassium
Blood
Flow rate
Pressure

ASJC Scopus subject areas

  • Pharmacology

Cite this

Asimakis, G. K., DiPette, D. J., Conti, V., Holland, O. B., & Zwischenberger, J. B. (1987). Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart. Life Sciences, 41(5), 597-604. https://doi.org/10.1016/0024-3205(87)90413-9

Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart. / Asimakis, Gregory K.; DiPette, Donald J.; Conti, Vincent; Holland, O. Bryan; Zwischenberger, Joseph B.

In: Life Sciences, Vol. 41, No. 5, 03.08.1987, p. 597-604.

Research output: Contribution to journalArticle

Asimakis, GK, DiPette, DJ, Conti, V, Holland, OB & Zwischenberger, JB 1987, 'Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart', Life Sciences, vol. 41, no. 5, pp. 597-604. https://doi.org/10.1016/0024-3205(87)90413-9
Asimakis, Gregory K. ; DiPette, Donald J. ; Conti, Vincent ; Holland, O. Bryan ; Zwischenberger, Joseph B. / Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart. In: Life Sciences. 1987 ; Vol. 41, No. 5. pp. 597-604.
@article{dd869bd9a85842e8a38591e81be6f95f,
title = "Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart",
abstract = "The effects of calcitonin gene-related peptide (CGRP) on heart rate, coronary flow, pressure development, and time to ischemic contracture were studied in the isolated, perfused rat heart. A bolus of CGRP (2640 pmols) caused significant increases in heart rate and coronary flow; these effects were sustained for at least five minutes after injection. The increase in coronary flow was independent of heart rate, since CGRP caused an increase in coronary flow in non-beating (potassium-arrested) hearts. The dose-response of CGRP was studied using five doses (65, 218, 658, 1320 and 2640 pmols) given as bolus injections. Although the increase in heart rate was apparently dose-dependent, significant increases above baseline were observed only with the two highest doses. In contrast, coronary flow increased significantly above baseline with the injection of all but the lowest dose of CGRP. Ten minutes after injection of CGRP, all hearts were made ischemic. The time to onset of ischemic contracture was approximately 11 minutes for those hearts that received 65 pmols CGRP; however, for those hearts receiving all other doses of CGRP, the time to onset of contracture was approximately 8 minutes. We conclude that CGRP significantly decreases the resistance of the coronary vascular bed, and that it may be an important regulator of regional blood flow in the heart.",
author = "Asimakis, {Gregory K.} and DiPette, {Donald J.} and Vincent Conti and Holland, {O. Bryan} and Zwischenberger, {Joseph B.}",
year = "1987",
month = "8",
day = "3",
doi = "10.1016/0024-3205(87)90413-9",
language = "English (US)",
volume = "41",
pages = "597--604",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Hemodynamic action of calcitonin gene-related peptide in the isolated rat heart

AU - Asimakis, Gregory K.

AU - DiPette, Donald J.

AU - Conti, Vincent

AU - Holland, O. Bryan

AU - Zwischenberger, Joseph B.

PY - 1987/8/3

Y1 - 1987/8/3

N2 - The effects of calcitonin gene-related peptide (CGRP) on heart rate, coronary flow, pressure development, and time to ischemic contracture were studied in the isolated, perfused rat heart. A bolus of CGRP (2640 pmols) caused significant increases in heart rate and coronary flow; these effects were sustained for at least five minutes after injection. The increase in coronary flow was independent of heart rate, since CGRP caused an increase in coronary flow in non-beating (potassium-arrested) hearts. The dose-response of CGRP was studied using five doses (65, 218, 658, 1320 and 2640 pmols) given as bolus injections. Although the increase in heart rate was apparently dose-dependent, significant increases above baseline were observed only with the two highest doses. In contrast, coronary flow increased significantly above baseline with the injection of all but the lowest dose of CGRP. Ten minutes after injection of CGRP, all hearts were made ischemic. The time to onset of ischemic contracture was approximately 11 minutes for those hearts that received 65 pmols CGRP; however, for those hearts receiving all other doses of CGRP, the time to onset of contracture was approximately 8 minutes. We conclude that CGRP significantly decreases the resistance of the coronary vascular bed, and that it may be an important regulator of regional blood flow in the heart.

AB - The effects of calcitonin gene-related peptide (CGRP) on heart rate, coronary flow, pressure development, and time to ischemic contracture were studied in the isolated, perfused rat heart. A bolus of CGRP (2640 pmols) caused significant increases in heart rate and coronary flow; these effects were sustained for at least five minutes after injection. The increase in coronary flow was independent of heart rate, since CGRP caused an increase in coronary flow in non-beating (potassium-arrested) hearts. The dose-response of CGRP was studied using five doses (65, 218, 658, 1320 and 2640 pmols) given as bolus injections. Although the increase in heart rate was apparently dose-dependent, significant increases above baseline were observed only with the two highest doses. In contrast, coronary flow increased significantly above baseline with the injection of all but the lowest dose of CGRP. Ten minutes after injection of CGRP, all hearts were made ischemic. The time to onset of ischemic contracture was approximately 11 minutes for those hearts that received 65 pmols CGRP; however, for those hearts receiving all other doses of CGRP, the time to onset of contracture was approximately 8 minutes. We conclude that CGRP significantly decreases the resistance of the coronary vascular bed, and that it may be an important regulator of regional blood flow in the heart.

UR - http://www.scopus.com/inward/record.url?scp=0023280264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023280264&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(87)90413-9

DO - 10.1016/0024-3205(87)90413-9

M3 - Article

VL - 41

SP - 597

EP - 604

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 5

ER -